Drugs / FOSCLEVUDINE ALAFENAMIDE
FOSCLEVUDINE ALAFENAMIDE
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05298332 | Mar → Aug 2022 | chronic hepatitis B virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 1 | NCT05137600 | Oct → Dec 2021 | — | Antios Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05137548 | Oct → Dec 2021 | — | Antios Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04248426 | Feb 2020 → May 2021 | chronic hepatitis B virus infection | Antios Therapeutics, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05238844 | Apr → May 2022 | chronic hepatitis B virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT04847440 | Mar 2021 → Sep 2022 | chronic hepatitis B virus infection, hepatitis D virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOSCLEVUDINE ALAFENAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095214 ↗ |
| Known as | AT-2173 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095214 ↗ |
| Known as | ATI-2173 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04248426 ↗ |
| Known as | Fosclevudina alafenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095214 ↗ |
| Action | Inhibit | “active site polymerase inhibitor” PMID 36201354 ↗ Oct 2022 |
| Modality | Other / unclassified | “ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine” NCT04847440 ↗ |
| Route | Oral | “It will be dosed as a capsule by mouth.” NCT04248426 ↗ |